OraSure Technologies, Inc. (OSUR) Position Boosted by Los Angeles Capital Management & Equity Research Inc.
Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 20.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,094 shares of the medical instruments supplier’s stock after buying an additional 3,444 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in OraSure Technologies were worth $260,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of OraSure Technologies by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 4,197,303 shares of the medical instruments supplier’s stock valued at $36,852,000 after buying an additional 225,800 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of OraSure Technologies by 29.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,494,674 shares of the medical instruments supplier’s stock valued at $21,903,000 after buying an additional 569,993 shares during the period. JPMorgan Chase & Co. raised its stake in shares of OraSure Technologies by 127.2% in the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after buying an additional 881,132 shares during the period. State Street Corp raised its stake in shares of OraSure Technologies by 6.3% in the fourth quarter. State Street Corp now owns 1,346,519 shares of the medical instruments supplier’s stock valued at $11,823,000 after buying an additional 79,922 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of OraSure Technologies by 6.7% in the fourth quarter. AQR Capital Management LLC now owns 1,190,046 shares of the medical instruments supplier’s stock valued at $10,449,000 after buying an additional 74,417 shares during the period. 88.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of OraSure Technologies, Inc. (NASDAQ OSUR) opened at 14.94 on Tuesday. The company has a market cap of $862.96 million, a price-to-earnings ratio of 28.62 and a beta of 1.60. The firm has a 50-day moving average of $14.90 and a 200 day moving average of $11.61. OraSure Technologies, Inc. has a one year low of $5.57 and a one year high of $15.90.
OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.04. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. The company had revenue of $32.55 million during the quarter, compared to the consensus estimate of $31.19 million. During the same quarter last year, the firm earned $0.04 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Equities research analysts anticipate that OraSure Technologies, Inc. will post $0.42 EPS for the current year.
Several equities research analysts have issued reports on OSUR shares. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Saturday, May 6th. Jefferies Group LLC boosted their price target on shares of OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $12.04.
In related news, CEO Douglas A. Michels sold 361,216 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $15.08, for a total value of $5,447,137.28. Following the transaction, the chief executive officer now owns 881,620 shares in the company, valued at $13,294,829.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronny B. Lancaster sold 89,684 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $14.79, for a total value of $1,326,426.36. Following the completion of the transaction, the director now owns 6,295 shares in the company, valued at approximately $93,103.05. The disclosure for this sale can be found here. Insiders have sold 929,639 shares of company stock valued at $13,924,004 in the last three months. Insiders own 7.80% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.